VLST, AnaptsyBio Developing Antibody Therapeutics for Autoimmune, Inflammatory Disorders
April 09, 2010
VLST, AnaptsyBio Developing Antibody Therapeutics for Autoimmune, Inflammatory Disorders
VLST, which uses an approach combining proteomics and bioinformatics to develop biologic therapeutics, would commercialize any product developed from the collaboration.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Samples Available for PRG 2012 Intra-Lab QC and Reproducibility Study
January 13, 2012 / ProteoMonitor - People in the News: Eric Bouvier; Alan Marshall; and More
January 13, 2012 / ProteoMonitor - NCI Kicks Off Second Stage of Clinical Proteomic Technologies for Cancer Initiative
August 26, 2011 / ProteoMonitor - Yale-Led Group Links Protein Markers to Kidney Injury in Cardiac Surgery Patients
August 26, 2011 / ProteoMonitor - Bio-Rad Develops More Sensitive, Streamlined Workflow for SPR-Mass Spec
August 26, 2011 / ProteoMonitor